Keratinocyte growth factor (KGF) is a 28-kDa heparin-binding member of the fibroblast growth factor (FGF) family (alternative designation = FGF-7) that specifically binds to the KGF receptor, a splice variant of FGF receptor 2, which is expressed only in epithelial tissues. KGF has been identified as an important paracrine mediator of proliferation and differentiation in a wide variety of epithelial cells, including hepatocytes and gastrointestinal epithelial cells, type II pneumocytes, transitional urothelial cells, and keratinocytes in all stratified squamous epithelia. Systemic administration of recombinant human KGF (rHuKGF) provides significant cytoprotection to epithelial tissues in a number of different animal models of epithelial/mucosal damage, including models of injury to the gastrointestinal tract, lung, urinary bladder, and hair follicles. The results obtained with these preclinical models prompted an investigation of the use of rHuKGF as a cytoprotective agent against radiation-and/or chemotherapy-induced oral and gastrointestinal mucositis. Several dose-and time-variable studies were conducted in normal rhesus macaques to determine the lowest dose and shortest duration of rHuKGF administration required to induce oral mucosal proliferation without other significant systemic effects. Numerous studies were also conducted in murine models of chemotherapy-induced mucositis to fine-tune the dosing schedule. These studies showed that 2-3 days of rHuKGF administration were sufficient to induce significant oral mucosal proliferation and to protect against gastrointestinal mucositis when administered prior to the initiation of chemotherapy. The results from these models were used to design a phase I study in normal human volunteers to evaluate the safety of rHuKGF and its ability to induce oral mucosal proliferation. rHuKGF was well tolerated and induced a significant increase in markers of oral mucosal proliferation following 3 days of administration at the highest doses. Phase I/II studies to evaluate the safety and efficacy of rHuKGF in the prevention of chemotherapy-induced mucositis are currently in progress.
INTRODUCTION
Keratinocyte growth factor (KGF) is a 28-kDa heparinbinding member of the fibroblast growth factor (FGF) family (alternative designation = FGF-7) that was initially isolated from pulmonary fibroblasts as a keratinocyte-stimulating activity (6, 15) . KGF specifically binds to the KGF receptor (KGFR), a splice variant of FGF receptor 2 (FGFR2) (11) . KGF is expressed only by mesenchymal cells, such as fibroblasts and hair follicular dermal papilla cells (Fig. lA, C) , while KGFR is expressed only by epithelial tissues, such as epidermis and intestinal epithelium, generally in very close proximity to cells that express KGF (Fig. 1B, D) (1, 5, 15) . BIOLOGIC 
ACTIVITIES OF KGF

Effects of KGF in Normal Animals
Many in vitro and in vivo studies have shown that KGF can induce proliferation and differentiation in a wide variety of epithelial cells. KGF stimulates proliferation of keratinocytes in the epidermis and oral mucosa and stimulates both proliferation and differentiation of keratinocytes in hair follicles and sebaceous glands (1) (2) (3) 15 ). In the gastrointestinal tract, KGF stimulates both proliferation and differentiation toward goblet cells (8) . Other epithelial cell types that KGF has been reported to stimulate include hepatocytes (8) , pulmonary type II pneumocytes (20) , mammary gland epithelial cells (19) , pancreatic ductal epithelial cells (24) , and transitional urothelial cells (22) . The results from all of these studies, coupled with the expression patterns of KGF and KGFR, have verified that KGF is an important mesenchymally expressed paracrine mediator of proliferation and differentiation in all or nearly all epithelial tissues.
Effects of KGF in Transgenic and Knockout Mice
Studies of transgenic mice in which KGF was overexpressed have extended our knowledge of the biologic roles of KGE Transgenic mice in which KGF was overexpressed in the lung via a surfactant protein C promoter developed fetal pulmonary cystadenomas rather than exhibiting normal pulmonary branching morphogenesis (17) , whereas transgenic mice in which KGF was overexpressed by hepatocytes and secondarily in serum via an apolipoprotein E promoter developed polycystic kidneys (12) . These 2 studies demonstrated the importance of KGF in normal pulmonary and renal development. Other studies with tissue-specific KGF-overexpressing transgenic mice confirmed the biologic effects seen following systemic administration of KGF: proliferation and differentiation in the skin, gastrointestinal tract, liver, pancreas, mammary gland, and prostate gland (10, 12) .
Studies with KGF-null and epidermal-targeted KGFRnull mice have confirmed the importance of KGF and KGF signaling in normal skin development, particularly in the normal development of hair follicles (1, 7, 21) . Mice null for KGF (kgf-/ -) were normal in every regard -Sixteen-day-old neonatal rat littermates are protected by rHuKGF against ARA-C chemotherapy-induced alopecia. A) Three rat pups with marked alopecia treated with ARA-C plus phosphate-buffered saline. B) Significant protection from alopecia in 3 rat pups that received 3 daily injections of rHuKGF at 5 [Lg/g body weight/day beginning 3 days prior to the initiation of ARA-C chemotherapy. except for exhibiting a rough and unkept hair coat (7) , whereas mice null for KGFR targeted to the epidermis and hair follicles exhibited thin skin, a very low density of hair follicles, and delayed wound healing (21) . Mice null for FGFR2, of which KGFR is a splice variant, targeted to the lungs, exhibited a complete absence of lungs (14) , confirming the importance of the KGF-KGFR signaling pathway in normal pulmonary development.
PRECLINICAL MODELS OF EPITHELIAL CYTOPROTECTION
Systemic administration of recombinant human KGF (rHuKGF) provides significant cytoprotection to epithelial tissues in a number of different animal models of epithelial/mucosal damage, including models of injury to the gastrointestinal tract, lung, urinary bladder, and hair follicles. In models of alopecia, pretreatment with r-HuKGF was able to protect against approximately 50% of the alopecia induced by cytosine arabinoside (ARA-C) ( Fig. 2 ) but could not protect against cyclophosphamide-induced alopecia (3) . In contrast, pretreatment with rHuKGF was able to protect against cyclophosphamideinduced ulcerative and hemorrhagic urinary cystitis (18) . rHuKGF pretreatment was also effective in preventing much of the damage and fibrosis associated with bleomycin-and radiation-induced pulmonary injury (23) .
The model in which rHuKGF pretreatment appeared to be most effective was in the protection of the gastrointestinal tract from chemotherapy-and radiotherapy-induced mucosal damage. In this model, rHuKGF pretreatment significantly protected mice from 5-fluorouracil (5-FU) and methotrexate chemotherapy-and radiotherapyinduced mortality and intestinal villus blunting and atrophy ( Fig. 3) (4, 9) . The results from these gastrointestinal protection studies prompted the investigation of the potential for rHuKGF as a cytoprotective agent against radiation-and/or chemotherapy-induced oral and gastrointestinal mucositis.
RHUKGF EFFECTS ON HUMAN TUMORS
. Because many epithelial tumors express KGFR, the potential for rHuKGF stimulation or protection of KGFR+ tumors in the clinical setting was recognized and addressed in several different studies. First, the effects of rHuKGF on the in vitro and in vivo growth of several different human colonic adenocarcinoma and squamous cell carcinoma cell lines was assessed. rHuKGF did not stimulate the growth of any of these tumor cell lines, either in vitro or when transplanted into athymic nude mice (4, 13) . Second, the effects of rHuKGF on in vitro and in vivo tumor cytoprotection against both chemo- therapy-and radiotherapy-induced damage were assessed. Again, rHuKGF did not afford significant chemoor radioprotection to any of the human colonic adenocarcinoma or squamous cell carcinoma cell lines, either in vitro or in vivo (4, 13) . The results from these studies strongly suggested that rHuKGF could afford significant protection against chemotherapyor radiotherapy-induced mucositis without either stimulating or protecting KGFR+ epithelial tumors.
PRECLINICAL DOSING AND SCHEDULING STUDIES
All of the initial gastrointestinal studies were done with high doses of rHuKGF in a murine model. Because previous in vivo studies indicated that rHuKGF was a potent epithelial growth factor that affected many tissues when given at high doses and/or over several consecutive days, several doseand time-variable studies in both murine mucositis models and normal rhesus macaques were conducted to determine the lowest dose and shortest duration Rhesus macaques were chosen for the oral mucosal studies because their oral mucosal morphology resembles that of humans more closely than does that of rodents. The results from these studies showed that as few as 2-3 days of rHuKGF treatment were sufficient to induce significant oral mucosal proliferation in rhesus macaques (Fig. 4 ) and to protect against gastrointestinal mucositis in mice (4) . The information gained from these studies was then used to design a phase I study in normal human volunteers.
RHUKGF IN HUMANS
A phase I clinical trial in normal, healthy human volunteers was designed to evaluate the safety of rHuKGF and its ability to induce oral mucosal proliferation following 3 days of systemic administration. The results demonstrated that 3 days of systemically administered rHuKGF was safe, well tolerated, and induced a significant, dose-dependent increase in mucosal Ki-67-labeling and mitotic figure counts, both markers of oral mucosal proliferation ( Fig. 5 ) (16) . Phase I/II studies to evaluate the safety and efficacy of rHuKGF in the prevention of chemotherapy-induced mucositis are currently in progress.
SUMMARY
In summary, KGF is an important mesenchymally expressed paracrine mediator of epithelial proliferation and differentiation. Preclinical studies demonstrated that rHuKGF could afford significant cytoprotection in several animal models of epithelial damage, particularly models of gastrointestinal mucositis. The optimal dosing schedule of rHuKGF was then determined by evaluating oral mucosal proliferation in rhesus macaques and cytoprotection in murine models of gastrointestinal mucositis. The information from these studies was used to design a phase I clinical trial in normal human volunteers. Results from this phase I trial demonstrated that rHuKGF was safe, well tolerated, and induced a significant increase in oral buccal mucosal proliferation.
The majority of our knowledge of the distribution, biology, and utility of KGF in preclinical animal models and its potential clinical efficacy was determined by pathologists using traditional morphologic analyses as well as morphometric and molecular pathology techniques. Specifically, pathologists played a vital role in the determination of the tissue distribution of KGF and KGFR and in the elucidation of KGF's biologic activities. Pathologists also developed a variety of preclinical animal models of epithelial damage and assessed the activities of rHuKGF in these animal model systems using morphologic and morphometric measures of proliferation and cytoprotection. The clinical dosing and scheduling for rHuKGF were also primarily based on morphologic and morphometric analyses in preclinical models. In addition, similar morphologic and morphometric analyses were critical in the determination of rHuKGF's activity in nor-mal human volunteers. Morphologic analyses by pathologists should continue to play an important role in ongoing rHuKGF clinical trials. ACKNOWLEDGMENTS I gratefully acknowledge the many investigators whose work has contributed to our current understanding of the biology of KGF, its activities in preclinical models, and its potential for clinical therapy. I also thank Sheila Scully for her very able assistance with the layout of most of the figures.
